

# Diabetic retinopathy - Pipeline Insight, 2021

<https://marketpublishers.com/r/DB3D54E33704EN.html>

Date: July 2021

Pages: 60

Price: US\$ 2,500.00 (Single User License)

ID: DB3D54E33704EN

## Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "Diabetic retinopathy - Pipeline Insight, 2021," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Diabetic retinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Diabetic retinopathy Understanding

#### Diabetic retinopathy: Overview

Diabetic retinopathy is a serious sight-threatening complication of diabetes. Diabetes interferes with the body's ability to use and store sugar (glucose). The disease is characterized by too much sugar in the blood, which can cause damage throughout the body, including the eyes. Over time, diabetes damages small blood vessels throughout the body, including the retina. Diabetic retinopathy occurs when these tiny blood vessels leak blood and other fluids. This causes the retinal tissue to swell, resulting in cloudy or blurred vision. Diabetic retinopathy usually affects both eyes. The longer a person has diabetes, the more likely they will develop diabetic retinopathy. If left untreated, diabetic retinopathy can cause blindness. When people with diabetes experience long periods of high blood sugar, fluid can accumulate in the lens inside the eye that controls focusing.

This changes the curvature of the lens, leading to changes in vision. However, once blood sugar levels are controlled, usually the lens will return to its original shape and vision improves. Patients with diabetes who can better control their blood sugar levels will slow the onset and progression of diabetic retinopathy.

'Diabetic retinopathy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic retinopathy pipeline landscape is provided which includes the disease overview and Diabetic retinopathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic retinopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic retinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic retinopathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic retinopathy.

## Diabetic retinopathy Emerging Drugs Chapters

This segment of the Diabetic retinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Diabetic retinopathy Emerging Drugs

### Brolucizumab: Novartis

Brolucizumab (RTH258) is a humanized single-chain antibody fragment (scFv) and the most clinically advanced, humanized single-chain antibody fragment to reach this stage of development. Single-chain antibody fragments are highly sought after in drug

development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation and drug delivery characteristics. The proprietary innovative structure results in a small molecule (26 kDa) with potent inhibition of, and high affinity to, all VEGF-A isoforms. In preclinical studies, brovacizumab inhibited activation of VEGF receptors through prevention of the ligand-receptor interaction. Increased signaling through the VEGF pathway is associated with pathologic ocular angiogenesis and retinal edema. Inhibition of the VEGF pathway has been shown to inhibit the growth of neovascular lesions, resolve retinal edema and improve vision in patients with choroidretinal vascular diseases. Currently, it is in Phase III stage of development to treat diabetic retinopathy.

#### RGX 314: Regenxbio Inc.

RGX-314 is being developed as a novel, one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for formation of new leaky blood vessels and retinal fluid accumulation. Currently, it is in Phase II stage of development to treat diabetic retinopathy.

Further product details are provided in the report.....

#### Diabetic retinopathy: Therapeutic Assessment

This segment of the report provides insights about the different Diabetic retinopathy drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Diabetic retinopathy

There are approx. 50+ key companies which are developing the therapies for Diabetic retinopathy. The companies which have their Diabetic retinopathy drug candidates in the most advanced stage, i.e. phase III include, Novartis.

#### Phases

DelveInsight's report covers around 50+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Diabetic retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic retinopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic retinopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic retinopathy drugs.

Diabetic retinopathy Report Insights

Diabetic retinopathy Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Diabetic retinopathy Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Diabetic retinopathy drugs?

How many Diabetic retinopathy drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic retinopathy?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetic retinopathy therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Diabetic retinopathy and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Novartis

Regenxbio Inc.

Boehringer Ingelheim

Bayer

RemeGen Co., Ltd.

Kubota Vision

Hoffmann-La Roche

Allegro Ophthalmics

MingSight Pharmaceuticals

Ocuphire Pharma, Inc.

Adverum Biotechnologies, Inc.

Applied Therapeutics

OcuNexus Therapeutics

Alcon

Aerpio Pharmaceuticals

EyeGene

Aerie Pharmaceuticals

OccuRx

NovaGo Therapeutics

HanAll Biopharma

Ascentage Pharma

AptaBio

BONAC corporation

CCRP Therapeutics

Curacle Co Ltd

Emerald Bioscience, Inc.

EnnovaBio

Everglades Biopharma

Excitant Therapeutics, LLC

Foresee Pharmaceuticals Co., Ltd.

Glycadia

Hengenix Biotech Inc

Kubota Vision Inc.

LUYE PHARMA

MIRAE CELL BIO

Novelty Nobility Inc

Noveome Biotherapeutics, Inc.

OliPass Corporation

Palatin Technologies Inc

PharmAbcine Inc

PYC Therapeutics

Retinset SL



## RIBOMIC

### Key Products

Brolucizumab

RGX 314

BI 764524

Runcaciguat

RC28-E

emixustat hydrochloride

RG7774

Luminate

MS-553

APX3330

ADVM-022

AT 003

HCB 1019

Nepafenac

Razuprotafib

EGT 022

OCX-063

NG 004

HL 190

UBX 1967

APX-1004

BNC-1601

CU06

FP-008

GLY 230

HLX04

Emixustat HCl

LY09004

NN2101

PMC-403

PYC-001

BSL01

RBM-008

## Contents

- Introduction
- Executive Summary
- Diabetic retinopathy: Overview
  - Causes
  - Mechanism of Action
  - Signs and Symptoms
  - Diagnosis
  - Disease Management
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
  - Comparative Analysis
- Brolucizumab: Novartis
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
  - Comparative Analysis
- RGX 314: Regenxbio Inc.
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
  
- Early Stage Products (Phase I)
  - Comparative Analysis
- LY09004: Luye Pharma
  - Product Description
  - Research and Development

Product Development Activities  
Drug profiles in the detailed report.....  
Preclinical and Discovery Stage Products  
    Comparative Analysis  
PYC-001: PYC Therapeutics  
    Product Description  
    Research and Development  
    Product Development Activities  
Drug profiles in the detailed report.....

Inactive Products  
    Comparative Analysis  
Diabetic retinopathy Key Companies  
Diabetic retinopathy Key Products  
Diabetic retinopathy- Unmet Needs  
Diabetic retinopathy- Market Drivers and Barriers  
Diabetic retinopathy- Future Perspectives and Conclusion  
Diabetic retinopathy Analyst Views  
Diabetic retinopathy Key Companies  
Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Diabetic retinopathy

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Diabetic retinopathy
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Diabetic retinopathy - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/DB3D54E33704EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DB3D54E33704EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970